Wallace Pharmaceuticals Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Wallace Pharmaceuticals Private Limited Pharmaceutical Export Portfolio Dataset — 4 Products, $2.0M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Wallace Pharmaceuticals Private Limited — Pharmaceutical Exporter Profile (2026) | 4 Products, $2.0M Trade | TransData Nexus

Wallace Pharmaceuticals Private Limited

Indian Pharmaceutical Exporter · Advanced Diabetes Medications Specialist · $2.0M Total Trade · DGFT Verified

Wallace Pharmaceuticals Private Limited is an Indian pharmaceutical exporter with a total trade value of $2.0M across 4 products in 3 therapeutic categories. Based on 44 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Gliclazide ($1.1M), Sulfasalazine ($534.9K), Famotidine ($200.0K).

Wallace Pharmaceuticals Private Limited — Export Portfolio & Destination Treemap

Wallace Pharmaceuticals Private Limited pharmaceutical export portfolio — 4 products across 3 therapeutic categories. Source: Indian Customs (DGFT).

Who is Wallace Pharmaceuticals Private Limited? — Company Overview & Market Position

Wallace Pharmaceuticals Private Limited, established on February 2, 1968, is a privately held Indian pharmaceutical company headquartered in Panaji, Goa. The company is owned by the Menezes family, who have a longstanding legacy in the Indian pharmaceutical industry. Over the decades, Wallace Pharmaceuticals has diversified its product portfolio to include medications across various therapeutic areas such as cardiology, gastroenterology, neurology, and respiratory diseases. Additionally, the company has a strong presence in the nutraceuticals and cosmeceuticals segments.

As of the latest available data, Wallace Pharmaceuticals has an authorized capital of ₹5.50 crore and a paid-up capital of ₹2.65 crore. The company's operations are active, with a workforce of over 2,000 employees. The registered office is located at 3rd Floor, Dempo Trade Centre Building, Patto Plaza, EDC Complex, Panaji 403001, Goa, India.

What Does Wallace Pharmaceuticals Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Gliclazide$1.1M 2

Product Portfolio — Top 4 by Export Value

Wallace Pharmaceuticals Private Limited exports 4 pharmaceutical products across 3 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Gliclazide	Advanced Diabetes Medications	$1.1M	22	0.4%	15
2	Sulfasalazine	Gastrointestinal	$534.9K	12	16.6%	2
3	Famotidine	Gastrointestinal	$200.0K	4	0.4%	14
4	Hydroxychloroquine	Antimalarial & Antiparasitic	$138.5K	6	0.1%	11

Wallace Pharmaceuticals Private Limited exports 4 pharmaceutical products across 3 therapeutic categories with a total export value of $2.0M. The top category is Advanced Diabetes Medications (55.7% of portfolio), followed by Gastrointestinal (37.2%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Wallace Pharmaceuticals Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Wallace Pharmaceuticals operates multiple manufacturing facilities to meet the demands of its diverse product portfolio. The Dharwad plant, commissioned on April 16, 2001, specializes in the production of tablets, capsules, and oral supplements, with a monthly production capacity of 3 million capsules, 30 million tablets, and 1.2 million oral powder sachets. Another facility in Nalagarh, commissioned in 2007, manufactures tablets, liquids, and dry syrups, covering a total area of 20,810 square meters with a production capacity of 24 million tablets. In 2023, Wallace Pharmaceuticals inaugurated a new manufacturing facility in Nalagarh, strategically designed to meet the demands of the regulated pharmaceutical market. This plant focuses on the production of external preparations, including topical solutions, ointments, creams, and gels, with a total covered area of 12,832 square meters and an annual production capacity of 68.04 million tubes.

3Key Leadership

The leadership team at Wallace Pharmaceuticals comprises several key executives:

Rajashekhar Rayanagoudar Basanagouda: Whole-Time Director, appointed on February 1, 2025.

Vinay Pinto: Director, appointed on February 25, 2002.

Rashmi Menezes: Managing Director, appointed on May 31, 2001.

Pankaj Kumar: Director, appointed on June 22, 2020.

Maria Emilia Dias Menezes: Director, appointed on December 9, 1997.

Cesar Mauricio Jose De Menezes: Managing Director, appointed on June 15, 2005.

These leaders play pivotal roles in steering the company's strategic direction and operations.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Wallace Pharmaceuticals Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Wallace Pharmaceuticals has made significant strides in obtaining regulatory approvals for its products in various international markets. The company has secured approvals from the U.S. Food and Drug Administration (FDA) for several of its generic formulations, enabling it to supply the U.S. market with high-quality, cost-effective alternatives. In the European Union (EU), Wallace Pharmaceuticals has obtained Good Manufacturing Practice (GMP) certifications, ensuring compliance with stringent EU standards. The company has also received approvals from the UK's Medicines and Healthcare products Regulatory Agency (MHRA), facilitating its presence in the UK market. In Australia, Wallace Pharmaceuticals has registered its products with the Therapeutic Goods Administration (TGA), allowing access to the Australian market. Additionally, the company has obtained regulatory approvals in Japan, further expanding its footprint in the Asia-Pacific region. These approvals underscore Wallace Pharmaceuticals' commitment to meeting international quality standards and its strategic focus on expanding its presence in regulated markets.

2Emerging Markets

Wallace Pharmaceuticals has strategically expanded its presence in emerging markets, including Africa, Latin America, and Southeast Asia. The company's products are available in several countries across these regions, addressing the growing healthcare needs of diverse populations. By obtaining World Health Organization (WHO) prequalification for certain products, Wallace Pharmaceuticals has enhanced its credibility and facilitated access to these markets. The WHO prequalification process ensures that the company's products meet international standards of quality, safety, and efficacy, thereby increasing their acceptance among healthcare providers and patients in these regions. This strategic approach aligns with Wallace Pharmaceuticals' goal of being a global leader in affordable niche healthcare solutions.

Wallace Pharmaceuticals Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Wallace Pharmaceuticals has made significant progress in obtaining approvals from the U.S. Food and Drug Administration (FDA) for its generic formulations. The company has successfully registered its manufacturing facilities with the FDA, ensuring compliance with U.S. regulatory standards. Additionally, Wallace Pharmaceuticals has received approvals for several Abbreviated New Drug Applications (ANDAs), allowing it to market its generic products in the U.S. market. The company has also filed Drug Master Files (DMFs) with the FDA, providing detailed information about the manufacturing processes and quality controls of its products. These filings demonstrate Wallace Pharmaceuticals' commitment to maintaining high-quality standards and transparency in its operations. The company's facilities have undergone FDA inspections, which have been completed satisfactorily, further affirming its adherence to regulatory requirements. These achievements underscore Wallace Pharmaceuticals' dedication to expanding its presence in the U.S. market and meeting the healthcare needs of American patients.

2WHO & EU GMP

Wallace Pharmaceuticals has obtained Good Manufacturing Practice (GMP) certifications from the European Union (EU), ensuring that its manufacturing processes meet the stringent quality standards required for the EU market. These certifications are a testament to the company's commitment to producing high-quality pharmaceutical products. Additionally, Wallace Pharmaceuticals has received World Health Organization (WHO) prequalification for certain products, further validating the quality, safety, and efficacy of its offerings. The WHO prequalification process involves rigorous evaluations, and obtaining this status enhances the company's credibility and facilitates access to international markets, particularly in developing regions. These certifications and approvals reflect Wallace Pharmaceuticals' dedication to maintaining high-quality standards and expanding its global footprint.

Wallace Pharmaceuticals Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

In the pharmaceutical industry, Wallace Pharmaceuticals faces competition from both domestic and international companies operating in similar therapeutic areas. Key competitors include established Indian pharmaceutical firms such as Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, and Cipla, as well as multinational corporations like Novartis and Pfizer. These competitors have extensive product portfolios and established market presences, posing challenges to Wallace Pharmaceuticals in terms of market share and brand recognition.

TransData Nexus Research · DGFT export records, industry analysisMar 2026

Frequently Asked Questions — Wallace Pharmaceuticals Private Limited

How many pharmaceutical products does Wallace Pharmaceuticals Private Limited export from India?

Wallace Pharmaceuticals Private Limited exports 4 pharmaceutical products across 3 therapeutic categories. The top exports are Gliclazide ($1.1M), Sulfasalazine ($534.9K), Famotidine ($200.0K), Hydroxychloroquine ($138.5K). Total export value is $2.0M.

What is Wallace Pharmaceuticals Private Limited's total pharmaceutical export value?

Wallace Pharmaceuticals Private Limited's total pharmaceutical export value is $2.0M, based on 44 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Wallace Pharmaceuticals Private Limited cover?

Wallace Pharmaceuticals Private Limited exports across 3 therapeutic categories. The largest are Advanced Diabetes Medications (55.7%, 1 products), Gastrointestinal (37.2%, 2 products), Antimalarial & Antiparasitic (7.0%, 1 products).

Get Full Wallace Pharmaceuticals Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.